Software Engineer Intern - 2027
Genesis Molecular AI
Summary
Genesis Molecular AI is building a world-class software team to solve problems in drug discovery through machine learning, biophysical simulation, and computational chemistry. We are looking for engineers excited to help develop new medicines and play a critical role in building out our software platform.
Job description
You will
- Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
- Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
- Help scale our core infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs
You are
- A strong software engineer who will write code quickly and uphold our code quality standards
- A deep thinker who reasons from first principles over pattern matching
- Interested in learning about biochemistry and the drug development process
Requirements
- Strong software engineering skills
- Ability to write code quickly while upholding code quality standards
- Reasons from first principles over pattern matching
- Interest in learning biochemistry and the drug development process
Benefits
- High-impact tools and products
- Strong technical coworkers
- Weekly ML/chemistry paper discussions
Company overview
Genesis Molecular AI is a pioneering biotechnology company headquartered in Burlingame, California, with additional facilities in San Diego and New York. The company specializes in developing foundation models for molecular artificial intelligence to revolutionize drug design and development. Genesis operates at the intersection of AI and biotechnology, utilizing its proprietary GEMS (Genesis Exploration of Molecular Space) platform to accelerate small molecule drug discovery. The platform integrates advanced AI algorithms with physics-based modeling to generate and optimize drug molecules, including the breakthrough Pearl diffusion model for protein-ligand structure prediction. Genesis has raised over $300 million in funding from prominent investors including Andreessen Horowitz, NVIDIA's NVentures, Fidelity, and BlackRock. The company maintains an internal drug pipeline targeting high-value therapeutic areas and has established strategic collaborations with major pharmaceutical companies like Gilead and Incyte. With a team of 51-200 employees, Genesis Molecular AI represents a leading force in AI-driven drug discovery, combining cutting-edge computational approaches with traditional pharmaceutical development to address complex biological targets and create novel therapeutics.